Table 1

Baseline characteristics and follow-up information divided according to quartiles of suPAR

Quartiles of suPAR
<2.75 ng/mL≥2.75 to <3.5 ng/mL≥3.5 to ≤4.6 ng/mL>4.6 ng/mLP
Number of participants167164166170
Female384448480.22
Age (years)46 ± 1355 ± 1160 ± 1159 ± 11<0.001
Diabetes duration (years)20 ± 1532 ± 1438 ± 1341 ± 12<0.001
eGFR (mL/min/1.73 m2)100 ± 1592 ± 1580 ± 1956 ± 26<0.001
UAER (mg/24 h)11 (7–20)13 (7–40)16 (9–74)64 (16–339)<0.001
HbA1c (mmol/mol)62 ± 1365 ± 1366 ± 1265 ± 130.012
HbA1c (%)7.8 ± 1.28.1 ± 1.28.2 ± 1.18.1 ± 1.20.012
LDL cholesterol (mmol/L)2.5 ± 0.72.5 ± 0.82.4 ± 0.62.4 ± 0.90.21
BMI (kg/m2)25 ± 326 ± 426 ± 925 ± 250.51
Antihypertensive drugs44717796<0.001
RAASi41667289<0.001
Smoking11162826<0.001
Systolic blood pressure (mmHg)126 ± 15130 ± 14136 ± 19135 ± 19<0.001
Diastolic blood pressure (mmHg)75 ± 975 ± 874 ± 1073 ± 100.014
Follow-up
 Cardiovascular events, n (%)2 (1.2)12 (7.3)32 (19.3)48 (28.1)<0.001
 Decline in eGFR ≥30%, n (%)6 (3.6)11 (6.7)19 (11.5)57 (33.3)<0.001
 Progression in albuminuria, n (%)5 (3.1)7 (4.3)9 (5.4)15 (8.8)0.11
 ESRD, n (%)0 (0)0 (0)1 (0.6)37 (22.0)<0.001
 Total mortality, n (%)2 (1.2)7 (4.3)12 (7.2)37 (21.6)<0.001
  • Data represent percentage, mean ± SD, or median (IQR) unless otherwise indicated. P values are for trend across quartiles.